# 510(k) SUMMARY

This 510(k) summary of safety and effectiveness information is being submitted in accordance with the requirement of SMDA 1990 and 21 CFR 807.92.

# VIDAS® Lyme IgG

# A. Submitter Information

Submitter's Name: Address:

bioMérieux SA   
Chemin de I'Orme   
69280 Marcy-I'Etoile - France   
Catherine FRITSCH   
$\mathtt { + 3 3 }$ 4 78 87 23 98   
$\yen 33$ 4 78 87 20 75   
September 2012

Contact Person: Phone Number: Fax Number: Date of Preparation:

# B. Device Name

Trade Name: Common Name: Classification Name:

VIDAS® Lyme IgG   
Lyme IgG Assay   
21 CFR 866.3830 - Treponema pallidum treponemal test   
reagents

# C. Predicate Device Name

Trade Name: Platelia ™ Lyme IgG

D. Device Description

The VIDAS Lyme IgG assay principle combines a two-step enzyme immunoassay sandwich method with a final fluorescent detection (ELFA). The Solid Phase Receptacle $( \mathsf { S P R } \mathbb { Q } )$ serves as the solid phase as well as the pipetting device for the assay. Reagents for the assay are ready-to-use and predispensed in the sealed reagent strips. All of the assay steps are performed automatically by the instrument. The reaction medium is cycled in and out of the SPR several times.

After a preliminary wash step and a sample dilution step, the sample is cycled in and out of the SPR. Antibodies to B. burgdorferi present in the specimen will bind to the B. burgdorferi antigen coating the interior of the SPR. Unbound sample components are washed away. Anti-human IgG antibodies conjugated with alkaline phosphatase will attach to the immunocomplex bound to the SPR wall. A final wash step removes unbound conjugate.

During the final detection step, the substrate (4-Methyl-umbelliferyl phosphate) is cycled in and out of the SPR. The conjugate enzyme catalyzes the hydrolysis of this substrate into a fluorescent product (4-Methyl-umbeliferone) the fluorescence of which is measured at $4 5 0 \ n m$ The intensity of the fluorescence is proportional to the quantity of anti-B. burgdorferi IgG antibodies present in the sample. At the end of the assay, results are automatically calculated by the instrument. A test value is generated and a report is printed for each test.

# E. Intended Use

The VIDAS Lyme IgG (LYG) assay is an automated qualitative enzyme immunoassay intended for use on the instruments of the VIDAS family in the presumptive detection of human lgG antibodies to Borrelia burgdorferi in human serum (plain or separation gel) or plasma (sodium heparin or lithium heparin). It should be used to test patients with a history and/or symptoms of infection with B. burgdorferi. All VIDAS Lyme IgG positive specimens should be further tested with a Western Blot IgG assay to obtain supportive evidence of infection with B. burgdorferi.

# F. Technological Characteristics Summary

A general comparison of the similarities and differences of the assays is presented in the table below.

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>VIDAS® Lyme IgG (LYG) Assay</td><td rowspan=1 colspan=1>Platelia™ Lyme IgG (K080012)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The VIDAS Lyme IgG (LYG) assay isan automated qualitative enzymeimmunoassay intended for use on theinstruments of the VIDAS family inthe presumptive detection of humanIgG antibodies to Borrelia burgdorferiin human serum (plain or separationgel) or plasma (sodium heparin orlithium heparin). It should be used totest patients with a history and/orsymptoms of infection with B.burgdorferi. All VIDAS Lyme IgGpositive specimens should be furthertested with a Western Blot IgG assayto obtain supportive evidence ofinfection with B. burgdorferi.</td><td rowspan=1 colspan=1>The Platelia ™M Lyme IgG Test is aqualitative test intended for use inthe presumptive detection ofhuman IgG antibodies to Borreliaburgdorferi in human serum orplasma (K3 EDTA, sodium heparinor sodium citrate). The ElA systemshould be used to test serum orplasma from patients with a historyand symptoms of infection with B.burgdorferi. All positive andequivocal specimens should bere- tested with a specific, second-tier test such as Western-Blot.Positive second- tier results aresupportive evidence of infectionwith B. burgdorferi. The diagnosisof Lyme disease should be madebased on history and symptoms(such as erythema migrans), andother laboratory data, in additionto the presence of antibodies toB. burgdorferi. Negative results(either first or second-tier) shouldnot be used to exclude Lymedisease.</td></tr><tr><td rowspan=1 colspan=1>Specimen</td><td rowspan=1 colspan=1>Serum or plasma</td><td rowspan=1 colspan=1>Serum or plasma</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>IgG antibodies to Borreliaburgdorferi</td><td rowspan=1 colspan=1>IgG antibodies to Borreliaburgdorferi</td></tr><tr><td rowspan=1 colspan=1>Automated</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>AssayTechnique</td><td rowspan=1 colspan=1>Enzyme-linked fluorescent assay(ELFA)</td><td rowspan=1 colspan=1>Enzyme immunoassay (EIA)</td></tr></table>

# G. Nonclinical Tests

A summary of the non-clinical results is presented below.

# Precision

For the precision study, 4 serum samples were tested in duplicate in 40 different runs (2 runs per day over 20 days) with 2 reagent lots at 1 site $( n = 8 0 )$ .The precision was calculated following the recommendations of the ${ \mathsf { C L S l } } ^ { \otimes }$ document EP5-A2. The total precision data in the table reflect the 80 values generated per sample for Site 1 and takes into account replicate, run, day, calibration, and lot as potential sources of variation. The total precision for controls include within-day, between-days and between-calibration variability and is lot specific.

<table><tr><td rowspan=2 colspan=1>Panel Member</td><td rowspan=2 colspan=1>N</td><td rowspan=2 colspan=1>MeanIndex</td><td rowspan=1 colspan=2>Within-run</td><td rowspan=1 colspan=2>Within-day</td><td rowspan=1 colspan=2>Between-days</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>9.7</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>5.4</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>18.5</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>18.3</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>6.8</td></tr><tr><td rowspan=1 colspan=1>High Positive</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>2.34</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>5.7</td></tr><tr><td rowspan=1 colspan=1>Positive Control</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.45</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>.NA</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>6.7</td></tr><tr><td rowspan=1 colspan=1>Negative Control</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td></tr></table>

# Reproducibility

For reproducibility, 4 serum samples were tested in duplicate in 40 different runs (2 runs per day over 20 days) with 2 reagent lots at $^ 3$ sites $( n = 2 4 0 )$ . The reproducibility was calculated following the recommendations of the ${ \mathsf { C L S l } } ^ { \otimes }$ document EP5-A2. The total reproducibility data in the table reflects the 240 values generated per sample for all sites and takes into account replicate, run, day, calibration, lot, and site as potential sources of variation. Out of the 240 total values, 2 high negatives gave a positive value and 2 low positives gave a negative value. The total reproducibility for controls include within-day, between-days, betweencalibration and between-site variability and is lot specific.

<table><tr><td colspan="1" rowspan="2">PanelMember</td><td colspan="1" rowspan="2">N</td><td colspan="1" rowspan="2">MeanIndex</td><td colspan="2" rowspan="1">Within-run</td><td colspan="2" rowspan="1">Within-day</td><td colspan="2" rowspan="1">Between-days</td><td colspan="2" rowspan="1">Between-site</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">$(v)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV(%%</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">$(v</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">$(v)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV (%)</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">0.11</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">7.6</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">4.3</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">3.8</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">15.5</td></tr><tr><td colspan="1" rowspan="1">HighNegative</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">0.15</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">8.6</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">3.3</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.02-</td><td colspan="1" rowspan="1">15.5</td></tr><tr><td colspan="1" rowspan="2">PanelMember</td><td colspan="1" rowspan="2">.</td><td colspan="1" rowspan="2">MeanIndex</td><td colspan="2" rowspan="1">Within-run</td><td colspan="2" rowspan="1">Within-day</td><td colspan="2" rowspan="1">Between-days</td><td colspan="2" rowspan="1">Between-site</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">$(v)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">(v)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">$(v)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">$(v)</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">CV (%)</td></tr><tr><td colspan="1" rowspan="1">LowPositive</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">0.26</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">5.4</td><td colspan="1" rowspan="1">0.01</td><td colspan="1" rowspan="1">3.9</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">7.7</td></tr><tr><td colspan="1" rowspan="1">HighPositive</td><td colspan="1" rowspan="1">240</td><td colspan="1" rowspan="1">2.31</td><td colspan="1" rowspan="1">0.10</td><td colspan="1" rowspan="1">4.1</td><td colspan="1" rowspan="1">0.04</td><td colspan="1" rowspan="1">1.8</td><td colspan="1" rowspan="1">0.03</td><td colspan="1" rowspan="1">1.2</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">0.12</td><td colspan="1" rowspan="1">5.3</td></tr><tr><td colspan="1" rowspan="1">PositiveControl</td><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">0.45</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA.</td><td colspan="1" rowspan="1">0.02</td><td colspan="1" rowspan="1">5.2</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0:03</td><td colspan="1" rowspan="1">6.3</td></tr><tr><td colspan="1" rowspan="1">NegativeControl</td><td colspan="1" rowspan="1">120</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">0.00:</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.00</td><td colspan="1" rowspan="1">0.0</td></tr></table>

# Interfering Substances

Specimen-related Interference: Interferences were studied according to the recommendations of $\operatorname { c L S I } ^ { \otimes }$ document EP7-A2. None of the following factors have been found to significantly influence this assay:

- hemolysis (hemoglobin: $5 9 / L$ (monomer)),   
- lipemia (lipids: $3 0 g / L$ equivalent in triglycerides),   
bilirubinemia (bilirubin: $0 . 3 \mathfrak { g } / \mathbb { L } )$   
- human albumin (albumin up to $6 0 g / L )$ .   
It is recommended not to use samples that are hemolyzed, lipemic or icteric and, if possible, to collect a new sample.

Exogenous Interferents: the potential interferences with 15 commonly used drugs were studied: no interference was observed at the concentration tested.

<table><tr><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Concentration tested</td><td rowspan=1 colspan=1>Drug</td><td rowspan=1 colspan=1>Concentrationtested</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic Acid</td><td rowspan=1 colspan=1>3.62 mmol/L</td><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>2425 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Amoxicillin</td><td rowspan=1 colspan=1>206 μmol/L</td><td rowspan=1 colspan=1>Minocycline</td><td rowspan=1 colspan=1>4.1 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Azithromycin</td><td rowspan=1 colspan=1>34 μmol/L</td><td rowspan=1 colspan=1>Penicillin G</td><td rowspan=1 colspan=1>240 000 U/L</td></tr><tr><td rowspan=1 colspan=1>Betamethasone</td><td rowspan=1 colspan=1>8.31 μmol/L</td><td rowspan=1 colspan=1>Penicillin Phenoxymethyl</td><td rowspan=1 colspan=1>30 000 U/L</td></tr><tr><td rowspan=1 colspan=1>Ceftriaxone</td><td rowspan=1 colspan=1>1460 μmol/L</td><td rowspan=1 colspan=1>Prednisolone</td><td rowspan=1 colspan=1>8.31 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Cefuroxime Axetil</td><td rowspan=1 colspan=1>1416 μmol/L</td><td rowspan=1 colspan=1>Roxithromycin</td><td rowspan=1 colspan=1>15.3 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Doxycycline Hyclate</td><td rowspan=1 colspan=1>16.1 μmol/L</td><td rowspan=1 colspan=1>Tetracyclines</td><td rowspan=1 colspan=1>67.5 μmol/L</td></tr><tr><td rowspan=1 colspan=1>Erythromycin</td><td rowspan=1 colspan=1>22.2 μmol/L</td><td rowspan=1 colspan=2></td></tr></table>

# H.Clinical Testing

# Sensitivity testing

202 retrospective samples from patients meeting a case definition of LD and confirmed positive for B. Burgdorferi infection were run on the VIDAS Lyme IgG assay and the predicate Lyme IgG assay.

For the predicate test, equivocal results were considered as positive for the evaluation. The following results were obtained:

<table><tr><td rowspan=1 colspan=1>Stage</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>VIDAS Lyme IgG% Sensitivity</td><td rowspan=1 colspan=1>Predicate LymeIgG% Sensitivity</td><td rowspan=1 colspan=1>Difference inproportions</td></tr><tr><td rowspan=1 colspan=1>Stage I(early localized,single lesion)1 - 30 days</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>49.6095% CI(&quot;) [40.3% -58.9%]</td><td rowspan=1 colspan=1>42.9095% CI [33.8% -52.3%]</td><td rowspan=1 colspan=1>+6.7%95% CI [(-6)% -(19)%]</td></tr><tr><td rowspan=1 colspan=1>Stage I1(early disseminated,multiple lesions)1 - 30 days</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>83.6095% CI [71.9% -91.8%]</td><td rowspan=1 colspan=1>54.1095% CI [40.8% -66.9%]</td><td rowspan=1 colspan=1>+29.5%95% CI [(14)% -(45)%]</td></tr><tr><td rowspan=1 colspan=1>Stage III(late disseminated)</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>90.9095% CI [70.8% -98.9%]</td><td rowspan=1 colspan=1>72.7095% CI [49.8% -89.3%]</td><td rowspan=1 colspan=1>+18.2%95% CI [(-4)% -(40)%]</td></tr><tr><td rowspan=1 colspan=1>All stages</td><td rowspan=1 colspan=1>202</td><td rowspan=1 colspan=1>64.4095% CI [57.3% -71.0%]</td><td rowspan=1 colspan=1>49.5095% CI [42.4% -56.6%]</td><td rowspan=1 colspan=1>+14.9%95% CI [(5)% -(24)%]</td></tr></table>

(1) $9 5 \%$ Confidence Interval.

# Method Comparison

A prospective study was performed on 975 fresh or frozen prospectively collected sera submitted for routine Lyme disease testing from an endemic area of the United States. Testing was performed in three laboratories.

At each laboratory, the samples were tested in parallel using a commercially available Lyme IgG EIA method (predicate) and the VIDAS Lyme IgG assay. Positive $\%$ Agreement (PPÁ) is calculated for the positives and equivocals together since the 2-tier testing does not make a distinction and calls for both of them to be tested by Western Blot. Combined results from the three sites are shown below:

<table><tr><td rowspan=1 colspan=1>N = 975</td><td rowspan=1 colspan=3>Predicate Lyme IgG</td></tr><tr><td rowspan=1 colspan=1>VIDAS Lyme IgG</td><td rowspan=1 colspan=1>eosod</td><td rowspan=1 colspan=1>Bnnc</td><td rowspan=1 colspan=1>Neelb</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>36</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>812</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>848</td></tr><tr><td rowspan=1 colspan=1>Positive % Agreement95% CI</td><td rowspan=1 colspan=3>74.0 % (94/127)[65.5% - 81.4%]</td></tr><tr><td rowspan=1 colspan=1>Negative % Agreement95% CI</td><td rowspan=1 colspan=3>95.8 % (812/848)[94.2% - 97.0%]</td></tr></table>

Second-Tier Testing: In accordance with the CDC recommendations for use of a 2-tier Lyme disease testing scheme, the VIDAS Lyme IgG positive results and the predicate Lyme IgG positive and equivocal results were confirmed using a commercially available Lyme IgG Western Blot method. The percent agreement between VIDAS and predicate Lyme IgG positives and the percent agreement between VIDAS-predicate-Western Blot IgG positives and Predicate-Western Blot IgG positives is shown below.

<table><tr><td></td><td>1st Tier + or t</td><td>IgG Western Pos.</td><td>Neg.</td></tr><tr><td>Predicate IgG</td><td>127</td><td>63</td><td>64</td></tr><tr><td>VIDAS IgG</td><td>130</td><td>65</td><td>65</td></tr><tr><td>VIDAS IgG and Predicate IgG</td><td>94</td><td>62</td><td>32</td></tr></table>

1 st tier $\mathsf { P P A } = 7 4 . 0 \ \%$ (94/127) $[ 9 5 \%$ CI; $6 5 . 5 \% - 8 1 . 4 \% ]$ $2 ^ { n d }$ tier $\mathsf { P P A } = 9 8 . 4 \%$ (62/63)  [95% CI; 91.47 - 99.96]

# Analytical Specificity

100 sera from apparently healthy subjects from an endemic population (New York) and 100 sera from a non-endemic population (Texas) with no known history of Lyme disease were run on the VIDAS Lyme $l g G$ assay and the predicate Lyme IgG assay. The following results were obtained:

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>VIDAS</td><td rowspan=1 colspan=2>Predicate</td></tr><tr><td rowspan=1 colspan=1>Positivity</td><td rowspan=1 colspan=1>Negativity</td><td rowspan=1 colspan=1>Positivity(1)</td><td rowspan=1 colspan=1>Negativity</td></tr><tr><td rowspan=1 colspan=1>Endemic</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>97.0%</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>97.0%</td></tr><tr><td rowspan=1 colspan=1>Non-Endemic</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>99.0%</td></tr></table>

)Includes positives and equivocals.

# CDC Reference Panel

The following information is from a serum panel obtained from the CDC and tested using the VIDAS Lyme IgG kit. The results are presented as a means to convey further information on the performance of this assay with a masked, characterized serum panel. This does not imply an endorsement of the assay by the CDC.

<table><tr><td rowspan=2 colspan=1>Time fromonset</td><td rowspan=1 colspan=3>VIDAS Lyme IgG</td><td rowspan=1 colspan=3>Western Blot IgG</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Agreementwith clinicalstatus</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Agreementwith clinicalstatus</td></tr><tr><td rowspan=1 colspan=1>Normals</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>100.0 %(5/5)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>100.00 %(5/5)</td></tr><tr><td rowspan=1 colspan=1>&lt; 1 month</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>40.0 %(2/5)</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>40.00 %(2/5)</td></tr><tr><td rowspan=1 colspan=1>1-2months</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>66.6 %(4/6)</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0.00 %(0/6)</td></tr><tr><td rowspan=1 colspan=1>3 - 12months</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>50.0 %(8/16)</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>43.75%(7/16)</td></tr><tr><td rowspan=1 colspan=1>&gt; 1 year</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100.0 %(717)</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100.00 %(717)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>66.6 %(26/39)</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>53.84%(21/39)</td></tr></table>

# Cross-Reactivity

Cross-reactivity is based on the study of samples that are negative with the test being evaluated and positive for the potentially interfering disease. The results of the samples tested according to the disease are shown in the table below:

<table><tr><td rowspan=1 colspan=1>Infection or Diagnosis</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>VIDAS LymeIgGpositiveresults</td><td rowspan=1 colspan=1>% Cross-reactivity</td></tr><tr><td rowspan=1 colspan=1>Anti Nuclear Antibodies</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>8.33</td></tr><tr><td rowspan=1 colspan=1>C Reactive Protein</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>3.28</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>Epstein Barr Virus</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>Helicobacter Pylori</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>1.40</td></tr><tr><td rowspan=1 colspan=1>Hepatitis A Virus</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2.00</td></tr><tr><td rowspan=1 colspan=1>HerpesSimplex Virus</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.80</td></tr><tr><td rowspan=1 colspan=1>HumanImmunodeficiency Virus</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5.00</td></tr><tr><td rowspan=1 colspan=1>Human Anti-mouseAntibodies</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>Leptospirosis</td><td rowspan=1 colspan=1>206</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>2.91</td></tr><tr><td rowspan=1 colspan=1>Measles</td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>Mumps</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>Rickettsiosis</td><td rowspan=1 colspan=1>133</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>2.25</td></tr><tr><td rowspan=1 colspan=1>Rubella</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td></tr><tr><td rowspan=1 colspan=1>Syphilis</td><td rowspan=1 colspan=1>256</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.39</td></tr><tr><td rowspan=1 colspan=1>Systemic LupusErythematosus</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>7.14</td></tr><tr><td rowspan=1 colspan=1>Toxoplasmosis</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>3.85</td></tr><tr><td rowspan=1 colspan=1>Varicella Zoster Virus</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.00</td></tr></table>

The effect of Babesiosis, Erhlichiosis and Rocky Mountain spotted fever pathologies on the VIDAS Lyme IgG performance is not known.

# I. Conclusion

The results from the nonclinical and clinical studies submitted in this premarket notification are complete and demonstrate that the VIDAS $\otimes$ Lyme IgG is substantially equivalent to the predicate device identified in Item C of this summary.

bioMerieux SA c/o Catherine FRITSCH Regulatory Affairs Director 5 rue des Aqueducs 69290 Craponne, France

Re: K122986 Trade/Device Name: VIDAS® Lyme IgG Regulation Number: 21 CFR 866.3830 Regulation Name: Treponema pallidum treponemal test reagents Regulatory Class: Class II Product Code: LSR Dated: January 25, 2013 Received: January 28, 2013

Dear Ms. FRITSCH:

We have reviewed your Section $5 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Tite 1, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostics and Radiological Health at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Sally A. Hojvat

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K122986

Device Name: VIDAS® Lyme IgG

Indications For Use:

The VIDAS Lyme IgG (LYG) assay is an automated qualitative enzyme immunoassay intended for use on the instruments of the ViDAS family in 'the presumptive detection of human IgG antibodies to Borrelia burgdorferi in human serum (plain or separation gel) or plasma (sodium heparin or lithium heparin). It should be used to test patients with a history and/or symptoms of infection with B. burgdorferi. All VIDAS Lyme IgG positive specimens should be further tested with a Western Blot IgG assay to obtain supportive evidence of infection with B. burgdorferi.